Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-6,page-paged-6,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
    www.inflarx.de
  • Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
    www.heidelberg-pharma.com
  • Adocia announces 2021 fourth quarter financial results
    www.adocia.com
  • dievini and related parties underline their strong commitment as shareholders of CureVac N.V. and do no longer plan to sell shares to the public
    www.dievini.de
  • Andera Partners supports TargED Biopharmaceuticals in €39 million Series A financing to bring groundbreaking thrombolytic treatment to patients
    www.anderapartners.com
  • Secarna Pharmaceuticals’ partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration
    www.secarna.com
  • InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
    www.inflarx.de
  • Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer
    www.topas-therapeutics.com
  • Marinomed receives € 6 m with final tranche of financing agreement with EIB to invest in proprietary R&D pipeline
    www.marinomed.com
  • AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus
    www.aicuris.com